Puretech provides end of year report on key progress

Boston--( business wire )--puretech health plc (nasdaq: prtc, lse: prtc) (“puretech” or the “company”), a clinical-stage biotherapeutics company dedicated to changing the treatment paradigm for devastating diseases, today reported on the key progress made across its wholly owned programs1 and founded entities2 in 2022.

PRTC Ratings Summary

PRTC Quant Ranking